ARWR Arrowhead Pharmaceuticals
- 21.870
- -1.420-6.10%
- 21.870
- 0.0000.00%
Arrowhead Pharmaceuticals News
Wolfe Upgrades Ionis to Outperform, Cites Upcoming Catalysts
Buy Rating Affirmed for Arrowhead Pharmaceuticals Following Promising Plozasiran Trial Results
Arrowhead Pharmaceuticals (ARWR) Receives a Buy From Piper Sandler
Analysts' Top Healthcare Picks: Edwards Lifesciences (EW), Arrowhead Pharmaceuticals (ARWR)
Arrowhead Pharma Analyst Ratings
Buy Rating Affirmed for Arrowhead Pharmaceuticals With Strong Growth Projections and Pipeline Potential
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Arrowhead Pharmaceuticals (ARWR)
Strategic Developments and Financial Strength Underpin Buy Rating for Arrowhead Pharmaceuticals
Arrowhead Pharma Analyst Ratings
RBC Capital Keeps Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Edwards Lifesciences (EW) and Doximity (DOCS)
Arrowhead Pharma Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), GoodRx Holdings (GDRX) and Johnson & Johnson (JNJ)
Buy Rating for Arrowhead Pharmaceuticals Amidst Pipeline Progress and Strategic Financial Positioning
Piper Sandler Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)
B of A Securities Maintains Buy on Arrowhead Pharma, Raises Price Target to $37
Arrowhead Pharma Analyst Ratings
Arrowhead Pharmaceuticals (ARWR) Gets a Buy From Piper Sandler
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Bioline RX Ltd Sponsored ADR (BLRX) and Arrowhead Pharmaceuticals (ARWR)
Arrowhead Pharmaceuticals: Strong Buy Rating Confirmed Amidst Strategic Milestones and Robust Pipeline Progress
Analysis
Price Target
No Data
